Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
ABBV

AbbVie Inc

ABBV

149.23USD+1.26 (+0.85%)Market Closed
Watchlist

Market Summary

USD149.23+1.26
Market Closed
0.85%

ABBV Alerts

  • Big fall in earnings (Y/Y)

ABBV Stock Price

View Fullscreen

ABBV RSI Chart

ABBV Valuation

Market Cap

263.7B

Price/Earnings (Trailing)

40.48

Price/Sales (Trailing)

4.78

EV/EBITDA

34.92

Price/Free Cashflow

10.66

ABBV Price/Sales (Trailing)

ABBV Profitability

EBT Margin

14.51%

Return on Equity

53.71%

Return on Assets

4.78%

Free Cashflow Yield

9.38%

ABBV Fundamentals

ABBV Revenue

Revenue (TTM)

55.1B

Revenue Y/Y

-5.97%

Revenue Q/Q

0.45%

ABBV Earnings

Earnings (TTM)

6.5B

Earnings Y/Y

-54.98%

Earnings Q/Q

-12.15%

Price Action

Last 7 days

4.1%

Last 30 days

5.1%

Last 90 days

0.1%

Trailing 12 Months

-10.1%

How does ABBV drawdown profile look like?

ABBV Financial Health

Current Ratio

0.96

Debt/Equity

4.59

Debt/Cashflow

0.46

ABBV Investor Care

Buy Backs (1Y)

0.17%

Diluted EPS (TTM)

3.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202356.7B56.0B55.1B0
202256.7B57.3B57.8B58.1B
202150.2B53.7B55.2B56.2B
202034.1B36.2B40.6B45.8B
201932.6B32.6B32.9B33.3B
201829.6B30.9B32.2B32.8B
201726.2B26.7B27.3B28.2B
201623.8B24.8B25.2B25.6B
201520.4B21.0B21.9B22.9B
201419.0B19.3B19.6B20.0B
201318.5B18.7B18.9B18.8B
201217.7B17.9B18.1B18.4B
201116.1B16.5B17.0B17.4B
201000015.6B

Latest Insider Trading transactions for ABBV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 25, 2023
gonzalez richard a
gifted
-
-
-42,000
chairman of the board and ceo
Sep 07, 2023
alpern robert j
acquired
-
-
129
-
Aug 01, 2023
gonzalez richard a
sold
-8,914,800
148
-60,000
chairman of the board and ceo
Jul 31, 2023
gonzalez richard a
sold
-2,759,280
149
-18,500
chairman of the board and ceo
May 11, 2023
strom carrie c
sold (taxes)
-421,104
146
-2,876
svp & pres global allerg aesth
May 05, 2023
burnside william h.l.
acquired
-
-
1,450
-
May 05, 2023
austin roxanne s
acquired
-
-
1,450
-
May 05, 2023
alpern robert j
acquired
-
-
1,450
-
May 05, 2023
freyman thomas c
acquired
-
-
1,450
-
May 05, 2023
roberts rebecca b
acquired
-
-
1,450
-

1–10 of 50

Which funds bought or sold ABBV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 07, 2023
DAGCO, INC.
added
0.08
121,925
1,258,060
0.65%
Dec 07, 2023
Financial Advisory Group
unchanged
-
60,874
633,207
0.13%
Dec 07, 2023
Hudson Bay Capital Management LP
added
27.39
18,234,500
62,769,800
0.25%
Dec 06, 2023
CITIGROUP INC
reduced
-13.16
-17,819,400
435,950,000
0.33%
Dec 06, 2023
Grant Street Asset Management, Inc.
reduced
-1.99
40,571
521,513
0.21%
Dec 06, 2023
Fragasso Group Inc.
added
1.5
198,082
1,810,150
0.19%
Dec 06, 2023
Raleigh Capital Management Inc.
added
0.06
237,057
2,450,950
1.30%
Dec 06, 2023
VisionPoint Advisory Group, LLC
added
2.13
164,954
1,434,520
0.62%
Dec 05, 2023
Advisory Resource Group
reduced
-10.26
-2,058
290,683
0.08%
Dec 05, 2023
Morton Capital Management LLC/CA
added
0.68
144,118
1,410,360
0.50%

1–10 of 46

Latest Funds Activity

Are funds buying ABBV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ABBV
No. of Funds

Schedule 13G FIlings of AbbVie Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 16, 2023
blackrock inc.
7.8%
138,702,758
SC 13G/A
Feb 09, 2023
vanguard group inc
8.95%
158,317,552
SC 13G/A
Feb 09, 2022
vanguard group inc
8.28%
146,312,069
SC 13G/A
Feb 03, 2022
blackrock inc.
7.3%
128,197,555
SC 13G/A
Feb 16, 2021
capital research global investors
2.1%
37,921,062
SC 13G/A
Feb 10, 2021
vanguard group inc
8.08%
142,563,074
SC 13G/A
Jan 29, 2021
blackrock inc.
7.0%
124,423,484
SC 13G/A
Feb 14, 2020
capital research global investors
5.8%
86,602,693
SC 13G/A
Feb 12, 2020
vanguard group inc
8.28%
122,574,720
SC 13G/A
Feb 05, 2020
blackrock inc.
6.7%
98,593,810
SC 13G/A

Recent SEC filings of AbbVie Inc

View All Filings
Date Filed Form Type Document
Dec 06, 2023
8-K
Current Report
Nov 30, 2023
8-K
Current Report
Nov 15, 2023
25-NSE
25-NSE
Nov 06, 2023
10-Q
Quarterly Report
Oct 27, 2023
8-K
Current Report
Oct 19, 2023
3
Insider Trading
Oct 19, 2023
3
Insider Trading
Oct 12, 2023
8-K
Current Report
Oct 04, 2023
8-K
Current Report
Oct 03, 2023
4
Insider Trading

ABBV Fair Value

Loading...

Peers (Alternatives to AbbVie Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.5B
102.8B
2.69% -12.25%
11.25
3.79
11.47% 80.74%
272.8B
59.3B
-0.63% -5.14%
17.88
4.63
0.58% -69.80%
162.5B
68.5B
-6.62% -44.42%
15.5
2.37
-31.38% -64.79%
144.0B
26.8B
-1.52% -4.93%
19.03
5.37
1.91% 10.69%
98.5B
27.4B
1.44% -10.10%
16.77
3.6
0.94% 76.21%
MID-CAP
11.0B
15.3B
7.32% 18.03%
-4.98
0.72
0.87% -71.24%
4.3B
1.6B
4.36% 1.49%
20.08
2.71
40.56% 266.27%
4.0B
4.7B
2.10% -7.72%
-978.12
0.86
5.74% 96.18%
2.7B
601.3M
24.99% 94.42%
20.1
4.52
24.02% 75.17%
2.7B
8.5B
1.81% -4.07%
-2.77
0.31
5.11% -479.13%
SMALL-CAP
1.4B
650.9M
10.34% -28.86%
-0.96
2.13
6.08% -185.21%
22.1M
-
-5.00% -65.05%
0.32
0.55
-19.54% 888.31%
15.2M
111.1M
27.41% 2089.90%
-0.96
0.14
-10.43% 84.90%
12.5M
-
39.62% -61.05%
-0.59
0.13
287.27% -145.15%
5.2M
20.0M
16.16% 1110.53%
-0.38
0.26
137.71% 66.04%

AbbVie Inc News

Latest updates
MarketBeat09 Dec 202308:39 am15 hours ago
MarketBeat08 Dec 202308:15 pm27 hours ago
InvestorsObserver08 Dec 202305:41 pm30 hours ago
Nasdaq08 Dec 202302:00 pm33 hours ago
Yahoo Finance07 Dec 202309:11 pm2 days ago
Investing.com UK07 Dec 202306:13 pm2 days ago
Investing.com Australia07 Dec 202305:07 pm2 days ago
AbbVie06 Dec 202309:31 pm3 days ago
StreetInsider.com06 Dec 202304:54 pm3 days ago
StockNews.com06 Dec 202303:54 pm3 days ago
WTOP06 Dec 202308:00 am3 days ago
Yahoo Finance05 Dec 202302:00 pm4 days ago
Yahoo Finance05 Dec 202304:00 am4 days ago
Bluefield Daily Telegraph04 Dec 202309:31 pm5 days ago
MarketBeat04 Dec 202308:14 pm5 days ago

Financials for AbbVie Inc

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue0.4%13,92713,86512,22515,12114,81214,58313,53814,88614,34213,95913,01013,85812,90210,4258,6198,7048,4798,2557,8288,3058,236
Costs and Expenses24.5%11,6469,3529,4579,61910,20911,2888,8219,81210,0369,5188,90710,1059,6479,6735,0164,7485,8624,8554,81810,7465,077
  S&GA Expenses3.2%3,3723,2683,0393,4173,3045,4123,1273,2603,0833,1642,8423,2312,8463,5271,6951,9511,6571,6541,6801,9291,919
EBITDA Margin-20.5%0.16*0.20*0.22*0.29*-0.26*0.31*0.29*--0.14*0.13*0.24*0.26*0.32*0.31*0.13*0.15*---
Income Taxes-70.5%172583234493448255436226508394312-1,54518746.0088.0027311766.0088.00-54714.00
Earnings Before Taxes-25.2%1,9532,6104752,9654,4001,1834,9294,2713,6881,1633,867-1,5072,500-6933,0983,0742,0018072,544-2,3732,761
EBT Margin-22.2%0.15*0.19*0.16*0.23*0.26*0.25*0.25*0.23*0.13*0.11*0.08*0.07*0.20*0.21*0.26*------
Net Income-12.2%1,7782,0242392,4733,9499244,4904,0443,1797663,55336.002,308-7383,0102,8011,8847412,456-1,8262,747
Net Income Margin-23.8%0.12*0.16*0.13*0.20*0.23*0.22*0.22*0.21*0.14*0.12*0.10*0.10*0.18*0.19*0.25*------
Free Cashflow19.8%7,3556,1414,0187,2157,4254,8624,7464,8887,7184,6954,6894,5755,6132,9123,690------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets0.6%136,221135,367134,544138,805141,325143,186143,211146,529148,858147,972150,501150,565149,621149,53091,19989,11559,44157,14256,76959,35266,164
  Current Assets15.2%33,22428,85226,48828,46330,36429,10026,50927,92828,95725,99926,56924,17323,00921,25651,75849,51920,16615,10014,41316,94518,465
    Cash Equivalents51.7%13,2878,7596,7119,20111,8328,5216,0989,74612,1828,5469,7558,4497,8906,01741,14239,92410,6485,1724,8977,2898,015
  Inventory-1.8%3,9814,0553,8333,5793,1723,3963,4833,1283,0943,3863,2723,3103,4744,0591,8441,8131,9291,8951,7021,6051,786
  Net PPE-0.2%4,9344,9434,9314,9354,8934,9585,0755,1105,1305,1615,1935,2484,9864,9082,9612,9622,8942,8792,8602,8832,950
  Goodwill-0.4%32,09132,22432,22032,15631,72632,02832,29832,37932,29632,39832,34933,12442,80142,66915,56115,60415,53715,64215,60615,66315,718
  Current Liabilities7.9%34,77332,23927,59029,53832,71234,47332,52135,19428,53328,68431,95128,66124,18124,64616,47115,58517,49316,94113,90417,23915,387
  Short Term Borrowings-2.00-1.001.0010.0017.0012.0014.0016.0017.009.0034.0054.0064.006.00--3064993,6993,002
  Long Term Debt-0.3%55,63155,81259,29259,13560,39961,00263,52264,18974,04974,23774,18377,55482,28282,06163,28462,97533,12631,61935,06635,00236,487
Shareholder's Equity-5.7%12,12912,86613,30317,25415,99414,68816,31415,43613,57712,59413,73313,09715,28914,732-------
  Retained Earnings-47.8%9331,7892,3934,7844,9533,5165,1033,1271,6007402,2921,0553,3353,1305,9734,7173,6733,3844,2343,3686,789
  Additional Paid-In Capital0.9%20,02119,83919,61919,24519,05618,90618,73118,30518,10817,93617,71217,38417,14816,95315,40115,19315,11215,02814,94014,75614,680
Shares Outstanding-100.0%-1,7671,770-1,7711,7701,771-1,7701,7691,769-1,7691,6471,481-1,4811,4801,480-1,511
Minority Interest9.4%35.0032.0029.0033.0033.0035.0031.0028.0027.0025.0023.0021.0019.0024.00-------
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations19.9%7,5746,3194,1937,4287,6025,0054,9085,0757,9354,8904,8774,8545,8303,0893,8153,2754,5552,4773,0173,3924,524
  Share Based Compensation-27.4%13017931313212610730612913515926913616223621979.0075.0087.0018970.0075.00
Cashflow From Investing-8.2%-369-341-499-4481,286130-1,591-1,145-615-242-342-627-1,149-35,652-129-6151,378-140-27.00-283-963
Cashflow From Financing32.1%-2,661-3,920-6,192-9,634-5,518-2,679-6,972-6,338-3,643-5,884-3,174-3,695-2,814-2,570-2,42226,602-441-2,070-5,383-3,825916
  Dividend Payments0.1%2,6272,6252,6612,5062,5042,5072,5262,3142,3152,3102,3222,1012,1001,7521,7631,5951,5911,5921,5881,4511,461
  Buy Backs-60.0%4.0010.001,9554.004.009.001,4701316.0010.0078729620.0019.006432.004.003.006202,0581,009

ABBV Income Statement

2023-09-30
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Net revenues$ 13,927$ 14,812$ 40,017$ 42,933
Cost of products sold6,4855,02214,71113,244
Selling, general and administrative3,3723,3049,67911,843
Research and development1,7231,6145,7484,720
Acquired IPR&D and milestones6640496454
Other operating expense (income), net0229(179)57
Total operating costs and expenses11,64610,20930,45530,318
Operating earnings2,2814,6039,56212,615
Interest expense, net3984971,3061,568
Net foreign exchange loss253697108
Other expense (income), net(95)(330)3,121427
Earnings before income tax expense1,9534,4005,03810,512
Income tax expense1724489891,139
Net earnings1,7813,9524,0499,373
Net earnings attributable to noncontrolling interest33810
Net earnings attributable to AbbVie Inc.$ 1,778$ 3,949$ 4,041$ 9,363
Per share data    
Basic earnings per share (in dollars per share)$ 1.00$ 2.22$ 2.27$ 5.26
Diluted earnings per share (in dollars per share)$ 1.00$ 2.21$ 2.26$ 5.24
Weighted-average basic shares outstanding (in shares)1,7671,7711,7681,771
Weighted-average diluted shares outstanding (in shares)1,7711,7761,7721,777

ABBV Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and equivalents$ 13,287$ 9,201
Short-term investments328
Accounts receivable, net11,41211,254
Inventories3,9813,579
Prepaid expenses and other4,5414,401
Total current assets33,22428,463
Investments275241
Property and equipment, net4,9344,935
Intangible assets, net58,60367,439
Goodwill32,09132,156
Other assets7,0945,571
Total assets136,221138,805
Current liabilities  
Short-term borrowings21
Current portion of long-term debt and finance lease obligations5,1134,135
Accounts payable and accrued liabilities29,65825,402
Total current liabilities34,77329,538
Long-term debt and finance lease obligations55,63159,135
Deferred income taxes2,0442,190
Other long-term liabilities31,64430,655
Commitments and contingencies
Stockholders' equity  
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,822,577,212 shares issued as of September 30, 2023 and 1,813,770,294 as of December 31, 20221818
Common stock held in treasury, at cost, 57,091,177 shares as of September 30, 2023 and 44,589,000 as of December 31, 2022(6,525)(4,594)
Additional paid-in capital20,02119,245
Retained earnings9334,784
Accumulated other comprehensive loss(2,353)(2,199)
Total stockholders' equity12,09417,254
Noncontrolling interest3533
Total equity12,12917,287
Total liabilities and equity$ 136,221$ 138,805
ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
 CEO
 WEBSITEwww.abbvie.com
 EMPLOYEES50000

AbbVie Inc Frequently Asked Questions


What is the ticker symbol for AbbVie Inc? What does ABBV stand for in stocks?

ABBV is the stock ticker symbol of AbbVie Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AbbVie Inc (ABBV)?

As of Fri Dec 08 2023, market cap of AbbVie Inc is 263.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABBV stock?

You can check ABBV's fair value in chart. The fair value of AbbVie Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AbbVie Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ABBV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AbbVie Inc a good stock to buy?

The fair value guage provides a quick view whether ABBV is over valued or under valued. Whether AbbVie Inc is cheap or expensive depends on the assumptions which impact AbbVie Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABBV.

What is AbbVie Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 08 2023, ABBV's PE ratio (Price to Earnings) is 40.48 and Price to Sales (PS) ratio is 4.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABBV PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AbbVie Inc's stock?

In the past 10 years, AbbVie Inc has provided 0.153 (multiply by 100 for percentage) rate of return.